Xenon Pharmaceuticals (XENE)
(Delayed Data from NSDQ)
$40.71 USD
-1.05 (-2.51%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $40.73 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$40.71 USD
-1.05 (-2.51%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $40.73 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Zacks News
Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%
by Zacks Equity Research
LBPH stock soars 52% on announcing that it is set to be acquired by Lundbeck for a total consideration of $2.6 billion to bolster the latter's neuro pipeline.
Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe
by Zacks Equity Research
ITCI is seeing strong Caplyta sales, driven by a high prescription rate. However, its heavy reliance on the drug's sales for growth is concerning.
Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures
by Zacks Equity Research
Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.
Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe
by Zacks Equity Research
Xenon's (XENE) clinical studies of azetukalner in epilepsy and other neurological disorders are progressing well. However, any setback is set to hurt the stock in the absence of a deep pipeline.
Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down
by Zacks Equity Research
Xenon (XENE) is down as it reports a wider-than-expected second-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
by Zacks Equity Research
Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Xenon (XENE) reports better-than-expected first-quarter 2024 earnings. Its development programs for azetukalner in epilepsy and MDD are progressing well.
What Makes Xenon Pharmaceuticals (XENE) a New Buy Stock
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus
by Zacks Equity Research
Xenon (XENE) reports mixed fourth-quarter 2023 financial results, wherein earnings beat estimates but revenues missed the same. Its development programs for XEN1101 in epilepsy and MDD are progressing well.
Here's Why You Should Add Xenon (XENE) to Your Portfolio Now
by Zacks Equity Research
Xenon's (XENE) late-stage studies in epilepsy are progressing well. The company is also gearing up to initiate a late-stage study for the MDD indication in 2024.
Wall Street Analysts Think Xenon Pharmaceuticals (XENE) Could Surge 25.76%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in Xenon Pharmaceuticals (XENE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Longboard Pharma (LBPH) Up on Upbeat Data From Epilepsy Study
by Zacks Equity Research
Longboard Pharma (LBPH) skyrockets 316% on positive data from phase Ib/IIa study of bexicaserin for the treatment of seizures associated with a broad range of epilepsy indications.
Xenon (XENE) Up on Top-Line Data From MDD Drug Phase II Study
by Zacks Equity Research
Xenon (XENE) posts top-line data from a phase II proof-of-concept study evaluating its pipeline candidate, XEN1101, for treating moderate-to-severe major depressive disorder. Stock rises.
Wall Street Analysts Believe Xenon Pharmaceuticals (XENE) Could Rally 36.75%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 36.8% in Xenon Pharmaceuticals (XENE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -4.35% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics (FATE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 6.90% and 86.61%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Gilead Sciences (GILD) Q2 Earnings Lag Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of -16.25% and 2.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -1.61% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Fortress Biotech (FBIO) Q1 Earnings Expected to Decline
by Zacks Equity Research
Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sutro Biopharma, Inc. (STRO) Soars 11.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Xenon Pharmaceuticals (XENE) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Incyte (INCY) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of -56.47% and 7.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 1.72% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sangamo (SGMO) delivered earnings and revenue surprises of 11.11% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -9.62% and 97.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?